Radar · Industry landscape · China
Life Sciences Landscape of China
3,218 Life Sciences companies in China, in one picture: who is hiring, who is raising money, who founded them, where they are based, what the news is about and where the research is going. Updated August 2026.
3,218companies tracked
$41.5Bdisclosed funding
34hiring right now
521events · 24 months
61,567news articles · 12 months
Who leads Life Sciences in China
Tracks 3,218 life‑sciences firms in China, highlighting the top hiring firms, best‑funded companies, and those currently hiring, with 34 firms hiring now and 572 firms reporting a funding round.
open roles
Hiring now
ranked by live open roles
- 01
Frankenman5last posted Jan 2026
- 02
Snibe4last posted Jul 2026
- 03
Nanochap3last posted May 2026
- 04
Argo Biopharma3last posted Dec 2025
- 05
REJOIN Medical Device2last posted Jul 2026
- 06
iCamumo2last posted Jun 2026
- 07
Ractigen2last posted May 2026
- 08
Dakewe Biotech2last posted Jun 2026
34 companies hiring · 4 posted in the last 30 days
disclosed funding
Most funded
disclosed totals, all rounds
- 01
Innovent Bio$1.1BPost IPO · Aug 2022
- 02
Abogen Biosciences$1.1BSeries C · May 2022
- 03
MGI$1BSeries B · May 2020
- 04
Tianjing Biological$867.9MPost IPO · Feb 2024
- 05
Sinovac$641.8MPost IPO · Dec 2020
- 06
CStone Pharma$610MPost IPO · Sep 2020
- 07
United Imaging Healthcare$503.6MSeries B · Jan 2018
- 08
Cornerstone Robotics$458.8MSeries D · Nov 2025
572 companies with disclosed rounds · $41.5B total
headcount
Largest teams
ranked by tracked headcount
- 01
Angel Yeast11,708tracked employees
- 02
United-Imaging5,172tracked employees
- 03
- 04
Remegen3,591tracked employees
- 05
- 06
Junshi BioPharma2,772tracked employees
- 07
Akeso2,520tracked employees
- 08
Cathay Biotech2,324tracked employees
72 companies with headcount data
share of events
Share of voice
share of all tracked sector news events, 24 months
- 01
Legend Biotechnology7.7%55 tracked events
- 02
- 03
- 04
Prenetics5.8%41 tracked events
- 05
ABM4.9%35 tracked events
- 06
Zai Lab4.5%32 tracked events
- 07
Burning Rock4.4%31 tracked events
- 08
Adagene3.5%25 tracked events
712 tracked events across 102 companies
articles
In the news
Prism news coverage, last 12 months
- 01
- 02
- 03
- 04
BGI80articles in the window
- 05
Sangon Biotech73articles in the window
- 06
Harbour BioMed72articles in the window
- 07
Sinopharm72articles in the window
- 08
135 of these companies drew sector coverage in the window
Radar
See all 3,218 Life Sciences companies in China
Filter by funding, headcount, hiring and location, and export the list.
How the Life Sciences ecosystem in China grew, 2016–2025
Shows the number of companies founded each year from 2016 to 2025, peaking at 255 new firms in 2017 and falling to five in 2025.
Companies founded / year
new Life Sciences companies in China
20162025
peak 255 in 2017
Companies raising / year
with a disclosed round that year
20162025
peak 148 in 2021
Disclosed funding / year
sum of disclosed rounds (USD)
20162025
peak $9.5B in 2020
Where Life Sciences companies in China are based
Hub 01
Shanghai
350 Life Sciences companies
23% of the Life Sciences companies across these hubs
350companies
$10.1Bdisclosed funding
6hiring now
Hub 02
Beijing
271 Life Sciences companies
18% of the Life Sciences companies across these hubs
271companies
$4.2Bdisclosed funding
4hiring now
Hub 03
Shenzhen
230 Life Sciences companies
15% of the Life Sciences companies across these hubs
230companies
$3.9Bdisclosed funding
4hiring now
Hub 04
Hangzhou
191 Life Sciences companies
13% of the Life Sciences companies across these hubs
191companies
$2.2Bdisclosed funding
3hiring now
Hub 05
Suzhou
167 Life Sciences companies
11% of the Life Sciences companies across these hubs
167companies
$5Bdisclosed funding
4hiring now
Hub 06
Hong Kong
112 Life Sciences companies
7% of the Life Sciences companies across these hubs
112companies
$978.1Mdisclosed funding
3hiring now
generated artwork
Hub 07
Guangzhou
110 Life Sciences companies
7% of the Life Sciences companies across these hubs
110companies
$1.1Bdisclosed funding
1hiring now
Hub 08
Nanjing
75 Life Sciences companies
5% of the Life Sciences companies across these hubs
75companies
$1.4Bdisclosed funding
The Life Sciences market map of China: what these companies actually do
Breaks down product sub‑categories and revenue models, noting healthtech (2,336 firms) and enterprise tech (2,107 firms) as the largest groups, with physical commerce and e‑commerce product as common revenue models.
- Healthtech2,336 companies · $40.6B raised · 32 hiring
- Enterprise Tech2,107 companies · $38.3B raised · 31 hiring
- Medical Devices771 companies · $6.4B raised · 12 hiring
- Biopharmaceuticals520 companies · $23.6B raised · 9 hiring
- Deep Tech474 companies · $10B raised · 4 hiring
- Consumer Digital232 companies · $825.5M raised · 3 hiring
- Enterprise Software220 companies · $2B raised · 2 hiring
- In Vitro Diagnostics127 companies · $2.4B raised · 2 hiring
- IoT in Healthcare101 companies · $240M raised · 1 hiring
- Chronic Disease Management101 companies · $788.4M raised · 4 hiring
- At Home Diagnostics92 companies · $217.3M raised · 1 hiring
- Cancer Immunotherapy90 companies · $3.6B raised · 1 hiring
Monetization
How Life Sciences companies make money
How many companies earn revenue each way. Plenty use more than one model, so the counts add up to more than the sector.
Physical Commerce1,875
E-Commerce - Product1,577
Fee-For-Service701
Subscription564
Commission on Transaction67
Advertising48
E-Commerce - Service31
Licensing1
Funding, M&A and the deals moving Life Sciences in China
Earnings 153Funding 90Leadership 63IPO 55M&A 44Announcement 36Contracts 33Board Updates 17Regulatory 11Lawsuit 6
- M&APhoenix Asia is pleased to announce entering into a stock acquisition agreement (the “Stock Acquisition Agreement”) with ACEA Pharma, Inc., ... for the acquisition of 100% of the issued and outstanding shares of common stock of Target Company.2026-05-04
- FundingPulnovo Medical has completed an oversubscribed $100m strategic financing round, with Medtronic as the lead investor. The round also included participation from existing investors such as EQT, Gaorong Ventures, Lilly Asia Ventures, OrbiMed and Qiming Venture Partners, along with new investors, including HSG (formerly Sequoia China). The financing will be directed towards clinical development, global regulatory submissions, international commercialisation, and investments in Pulnovo’s technology platform.2026-04-20
- FundingThe biotechnology company Oricell Therapeutics has raised more than 110 million dollars in its last round of funding prior to its release on the stock market, consolidating its position in the development of advanced cellular therapies, especially in the field of CAR-T therapy.2026-04-13
- M&AAs part of the acquisition, Meili Technology acquired all shares (100 percent) in Hitched Holdings 3 B.V. (“HH3”) from Hitched Holdings 2 B.V.2026-04-09
- IPOFor investors, this strategic step means a noticeable loss in the account, although the operating business is partly shiny.2026-03-25
- IPOBioMap, a life science AI model company founded by Baidu CEO Robin Li Yanhong, has reportedly filed a confidential application in Hong Kong, aiming to raise several hundred million US dollars.2026-03-17
- IPOGenFleet Therapeutics (GFT) raised around US$240m in its Hong Kong IPO in September 2025.2026-03-17
- FundingLeman Biotech, a cell therapy developer, has raised nearly RMB 200 million (USD 28 million) in a new round jointly led by Yuecai Zhongyin Private Equity and XtalPi, other participants include Kuangshi Zhixing, Mony Valley, Tailong VC, Zhongshan Investment Holdings, and individual investors, with existing shareholder Fuho Capital increasing its stake.2026-03-10
- FundingMetaNovas, an AI‑driven drug discovery company, has completed its Series A+ and Series A++ rounds with backing from GRC SinoGreen Capital, Hillhouse Capital, and Kangaroo Mommy Group, among other investors. Its earlier Series A round was co‑led by GL Ventures and Pagoda Top Capital, with participation from Ruoyuchen.2026-03-10
- FundingQL Biopharm , a biotechnology company focused on recombinant protein therapeutics, has secured over RMB 500 million (USD 70 million) in a Series C round led by OrbiMed.2026-03-03
Mergers and acquisitions
Deals from the last 24 months where a Life Sciences company in China was the buyer or the one bought, newest first. “Undisclosed” means the price was never published — not that the deal was worth nothing.
| Acquirer | Target | Deal value | Status | Date |
|---|---|---|---|---|
| Phoenix Asia Holdings Limited | $1B | Announced | 2026-05-04 | |
| Hitched Holdings 3 B.V. (HH3) | undisclosed | Announced | 2026-04-09 | |
| undisclosed | Announced | 2026-03-10 | ||
| undisclosed | Completed | 2026-02-06 | ||
| undisclosed | Announced | 2026-01-20 | ||
| $100M | Announced | 2026-01-20 |
Who is listing, hiring leaders, launching and winning work
Details specific event types such as IPO filings, leadership changes, product launches and contract wins for companies in the sector.
IPO pipeline
32 companies listed or filing · last 24 months
Impact TherapeuticsIPO · Hong Kong · 1 reportMay 2026
GenFleet TherapeuticsIPO · Hong Kong · GFT · 1 reportMar 2026
BioMapIPO · 1 reportMar 2026
Insight LifetechIPO · Shanghai Stock Exchange\'s STAR Market · 688712.SH · 3 reportsFeb 2026
Souzhou Ribo Life ScienceIPO · Hong Kong · 2 reportsJan 2026
Ascentage PharmaIPO · NASDAQ · AAPG · 4 reportsJan 2026
Geneplus TechnologyIPO · Hong Kong Stock Exchange · 1 reportDec 2025
Leadership moves
16 tracked people moves · last 12 months
Suzhou Connect BiopharmaceuticalsDr. Quart · Appointment → Chief Executive OfficerFeb 2026
Contract wins
24 customer wins · last 24 months
Antengenewon ucbMar 2026
InnoCarewon zenas biopharmaDec 2025
Regulatory & litigation
14 regulatory events · 5 tracked suits · 24 months
Sciwindreceived regulatory approvalFeb 2026
- SAIF Partners IV L.P., OrbiMed Partners Master Fund Limited, v sinovac biotechSpecial Shareholders Meeting dispute · OngoingDec 2025
- 1globe v sinovac biotechdirector election dispute · VerdictJun 2025
Earnings pulse
companies reporting results · last 24 months
30 companies reporting161 company-quarters trackedbeat 23miss 2in line 0
Half of these companies grew revenue faster than +36.8%, half slower.
Who is building Life Sciences in China
Profiles 1,218 founders and CEOs across 980 firms, showing that Tsinghua University (12 alumni) and Peking University (8 alumni) are the most common alma maters, with Google and Intel as frequent prior employers.
Founders and chief executives12 of 1,218, from the best-funded companies on this page
Founder Expro, ex-Moderna, Trucode Gene Repair. Fudan University, Northeastern University PhD
Co-Founder-MGI, BGI Group
Ex-Crown Bioscience, Pfizer, PDL BioPharma, Bayer, Axys Pharmaceuticals. Sun Yat-Sen University BS, Newcastle University PhD
CEO 3D Personalized Drug Discovery Center, Chinese Academy of Sciences PhD 2008, University of Zurich 2010…
Ex-GlaxoSmithKline, Ambrilia Biopharma. Nanjing University, University of Arizona PhD
Ex-Merck, Gilead Sciences, Novartis, Amgen, Chiron, GlaxoSmithKline, Genentech. Nanjing University, University of Maryland PhD
University of Medicine and Dentistry NJ
Ex-NanoMab, Founder Novus Life Sciences, Bao Kang Biomedical Healthcare. UNSW BSc 2007, The University of Hong Kong PhD 2012.
Haihe Biopharma, ex-Merck, ex-Bristol Myers Squibb Princeton New Jersey, Dana-Farber Cancer Institute, 1999
Where the founders studied
alma mater on record for 101 of 1,218 founders
Tsinghua University12
Peking University8
Harvard University8
University of Cambridge7
Hong Kong University of Science and Technology (HKUST)5
University of Chicago5
Massachusetts Institute of Technology5
The University of Hong Kong4
Where they worked before
a previous employer on record for 7 of 1,218 founders
Google2
Intel2
Microsoft1
Morgan Stanley1
Boston Consulting Group1
Founders flagged as repeat founders
of 1,088 founders with a profile on this page
3
carry a repeat-founder flag
- flagged as repeat founders3
- no repeat-founder flag1,085
Radar
Look up the people behind Life Sciences companies in China
Search founders, executives and operators by company, role and location.
Who funds Life Sciences in China
Records 1,870 funding rounds since 2016 from 1,624 investors, with the typical round size of $20.4 million.
| Investor · most active investors since 2016 | Rounds | Led | Latest |
|---|---|---|---|
| Qiming Venture Partners | 90 | 44 | Apr 2026 |
| Lilly Asia Ventures | 64 | 27 | Apr 2024 |
| Legend Capital | 59 | 26 | May 2026 |
| Hillhouse | 55 | 33 | Oct 2025 |
| Shenzhen Capital Group | 41 | 19 | May 2026 |
| IDG Capital | 39 | 21 | Dec 2025 |
| Sequoia Capital China | 37 | 25 | Feb 2023 |
| CDH | 37 | 22 | Mar 2026 |
| Yuanbio Venture Capital | 36 | 18 | Dec 2025 |
| Matrix Partners China | 36 | 16 | Dec 2025 |
Stage mix · rounds since 2016
Seed & Angel467
Series A–B1,026
Series C+ / PE303
Grants, debt & other74
The typical round is $20.4M — half were bigger, half smaller.
The biggest Life Sciences funding rounds in China
Highlights the largest disclosed round—a $1 billion Series B for MGI—and lists ten other large recent funding rounds.
| Company | Round | Size | When | Backers |
|---|---|---|---|---|
| Series Bmega-round | $1B | May 2020 | IDG Capital, CPE, Huatai Zijin Investment +8 more | |
| Series Cmega-round | $720M | Aug 2021 | Temasek, GL Ventures, Invesco +23 more | |
| Series Bmega-round | $503.6M | Sep 2017 | China Life Investment, SDIC Innovation, CITIC Securities +3 more | |
| Series Dmega-round | $315M | Apr 2023 | CBC Group, Mubadala | |
| Series Dmega-round | $300M | Aug 2022 | ADIA, GIC, China Life Insurance | |
| Series Cmega-round | $300M | Nov 2021 | SoftBank Vision Fund, 5Y Capital, Chimera +6 more | |
| Series Bmega-round | $290M | Apr 2023 | Greenwoods Investments, CPE, Gl-investment +4 more | |
| Series Dmega-round | $260M | Nov 2016 | Ping An, Taikang Insurance Group, Legend Capital +4 more | |
| Series Bmega-round | $260M | May 2018 | GIC, Yunfeng Capital, 6 Dimensions Capital +10 more | |
| Series C | $230M | Feb 2021 | GL Ventures, Temasek, Delos Capital +2 more |
Venture round sizes · 2023–2025
<$1M2
$1–10M15
$10–50M93
$50–250M35
>$250M2
147 venture rounds with a disclosed amount in the window.
Fresh cheques · last 6 months
Series D$110MMay 2026
Series C$50MMay 2026
Series A$40MMay 2026
Series A$17.5MMay 2026
Series E$145MApr 2026
Series D$110MApr 2026
What the news says about Life Sciences in China
Indexes 61,567 news articles from the last year, most often covering COVID‑19 vaccine work, oncology advances, drug pricing, and generic drug development.
News volume
Life Sciences coverage across China · articles per quarter
2021Q22026Q1
peak 13,612 in 2025Q1 · 61,567 articles in the last 12 tracked months
Tone of coverage
share of articles by dominant sentiment (positive / neutral / negative)
202120232025
Positive-tone share moved 70% → 80%, negative 29% → 18% across 2021–2025.
What the coverage is about
The subjects that dominate Life Sciences news in China. The arrow shows whether each one is being written about more or less than a year ago.
- Covid-19 vaccine development and efficacy trials5,396▲+57%
- Oncology and targeted therapy advancements5,153→+4%
- Drug pricing and reimbursement strategies4,950▲+30%
- Generic drug development and market trends3,304▲+28%
- Pharmaceutical marketing and sales strategies2,900▲+47%
- Rare disease therapies and orphan drugs2,768▲+21%
- Pharmaceutical supply chain management2,698▲+60%
- Covid-19 vaccination campaigns and rollout strategies2,581▲+47%
- Vaccine research and production methods2,497▲+18%
- Gene therapy and crispr technologies2,326▲+42%
Most-covered companies · last 12 months
- 148
- 99
- 83
- 80
- 73
- 72
- 72
- 55
- 53
- 46
135 Life Sciences companies here were named in the news over this period.
Prism
Watch Life Sciences coverage in China as it happens
Prism follows these subjects story by story — which companies are named, what is said about them and how the tone moves.
Momentum
The words getting louder — and quieter
Which terms are showing up in more stories than a year ago, and which are fading. The percentage is the change in how many articles mention them.
generic drug approval+41%drug repurposing ai+84%stem cell banking+53%vaccine candidates+41%diagnostic biotechnology+43%synthetic biology+68%machine learning drug discovery+71%pharma digital strategy+48%vaccination campaigns+54%gene delivery systems+52%
stock indices-44%capital markets-35%core inflation rate-64%monetary stance shift-55%monetary easing-53%
The pressures the press keeps returning to
Three recurring angles in China Life Sciences coverage, and whether each is getting more attention year on year (through 2025).
Regulatory Risk ▲ rising
42,274 articles touch this dimension · 52.5% critical tone
20212025
signals: vaccine candidates, vaccine trials, vaccine immunogenicity
Funding Momentum ▲ rising
13,456 articles touch this dimension · 55.9% critical tone
20212025
signals: vaccine candidates, vaccine innovation funding, global health vaccine financing
Growth ▲ rising
42,182 articles touch this dimension · 36.8% critical tone
20212025
signals: biosimilar market entry, earnings report, drug distribution
Life Sciences jobs in China: who is hiring and what they ask for
Reports zero job postings in the past year from two employers, with the most‑requested skills being PowerPoint, biology, biopharma, medical science and life science.
0postings · last 12 months
5postings tracked overall
2employers advertising
Demand
The Skills Employers Ask For
What Life Sciences employers in China put in their job ads. The bar is how many postings ask for it; the arrow shows whether demand grew or shrank against the year before.
- ppt1▼
- biology1▼
- biopharma1▼
- medical science1▼
- life science1▼
Most advertised titles
- 4
What Life Sciences research is working on
Summarizes 53,147 academic papers, of which 23,660 identify opportunities, 4,958 describe common problems, and 1,880 issue cautions.
How this field talks about itself
Life Sciences papers (gold) against all published research (grey)
Descriptive40.2% · 17.4%2.3×
Promising30.4% · 37.1%0.8×
Breakthrough14.1% · 26.4%0.5×
Problem-identifying8.3% · 9.7%0.9×
Cautionary3.5% · 4.6%0.8×
Comparative2.4% · 4.0%0.6×
Life Sciences literature runs 2.3× more “descriptive” than science at large (40.2% vs 17.4% baseline).
How the work is done
Empirical48.8%
Reviews37.2%
Methods-led11.2%
Position pieces2.2%
Theoretical0.6%
How the research reads
80% positive · 16% neutral · 4% negative, across 53,147 papers.
The institutions behind the field
- 87k
- 75k
- 61k
- 49k
- 43k
- 38k
ranked by how often their work is cited
Researchers who shaped it
Ahmad Almilaji · Reiki Nishimura · Tomofumi Osako · Yasuyuki Nishiyama · Rumiko Tashima · Masahiro Nakano · Glenn R. Gibson · Gregor Reid
The most-cited breakthroughs
- Copper-Zinc Superoxide Dismutase (SOD1) Is Released by Microglial Cells and Confers Neuroprotection against 6-OHDA Neurotoxicity · 9k cites
- In situ click chemistry generation of cyclooxygenase-2 inhibitors · 8k cites
- U1 snRNP regulates cancer cell migration and invasion in vitro · 7k cites
- Comprehensive molecular profiling of lung adenocarcinoma · 6k cites
- Lanthanum Chloride Inhibits LPS Mediated Expressions of Pro-Inflammatory Cytokines and Adhesion Molecules in HUVECs: Involvement of NF-κB-Jmjd3 Signal · 6k cites
Common problems researchers identify4,503 papers · 7 recurring themes
Problems · theme 01
Sustainable Biofuel and Biorefinery Challenges
781 papers · 17.3% of this block
▲ +11% share2022→2025 share of research on this subject
Researchers highlight limits in using microbes and plant biomass for eco‑friendly fuel and bioproduct production.
Biofuel · Synthetic biology · Biomass · Biorefinery
“A review on the plant microbiome: Ecology, functions, and emerging trends in microbial application”
781 of these papers raise it as a problem
Problems · theme 02
Food Safety and Processing Risks
757 papers · 16.8% of this block
▲ +41% share2022→2025 share of research on this subject
Papers discuss microbial hazards, nutritional impacts, and safety gaps in modern food processing and products.
Food safety · Food processing · Food products · Human health
“Microbial Risks in Food: Evaluation of Implementation of Food Safety Measures”
757 of these papers raise it as a problem
Problems · theme 03
Gene Expression and mRNA Therapeutics Issues
711 papers · 15.8% of this block
▼ -31% share2022→2025 share of research on this subject
Studies point to obstacles in controlling gene expression, mRNA stability, and cell‑culture models for therapies.
Messenger RNA · Gene · Cell culture · Gene expression
“Analysis of Cancer Metabolism by Imaging Hyperpolarized Nuclei: Prospects for Translation to Clinical Research”
711 of these papers raise it as a problem
Problems · theme 04
Crop Nutrition and Food‑Security Bottlenecks
693 papers · 15.4% of this block
▲ +23% share2022→2025 share of research on this subject
Works examine inefficiencies in fertiliser use, germplasm traits, and breeding for resilient, high‑yield crops.
Agriculture · Crop · Food security · Germplasm
“Revisiting fertilisers and fertilisation strategies for improved nutrient uptake by plants”
693 of these papers raise it as a problem
Problems · theme 05
Plant Disease Management Constraints
691 papers · 15.3% of this block
▲ +35% share2022→2025 share of research on this subject
Research reveals gaps in integrated pest management, host resistance, and pathogen‑vector dynamics.
Fungicide · Integrated pest management · Host · Disease management
“Innate Immunity in Plants: An Arms Race Between Pattern Recognition Receptors in Plants and Effectors in Microbial Pathogens”
691 of these papers raise it as a problem
Problems · theme 06
Antimicrobial Resistance Across Sectors
447 papers · 9.9% of this block
▲ +10% share2022→2025 share of research on this subject
Papers document rising antibiotic resistance in humans, livestock, and the environment and its drivers.
Antibiotic resistance · Antimicrobial · Antibiotics · Drug resistance
“Antimicrobial resistance in humans, livestock and the wider environment”
447 of these papers raise it as a problem
Problems · theme 07
Data Quality and Reporting Inconsistencies
423 papers · 9.4% of this block
▼ -32% share2022→2025 share of research on this subject
Analyses expose variability in methodological reporting and interdisciplinary communication challenges.
Order · NAD+ kinase · Human being · Sodium
“Modalidade, polaridade e legibilidade em resumos académicos: uma análise comparativa multidisciplinar”
423 of these papers raise it as a problem
Cautions1,765 papers · 7 recurring themes
Cautions · theme 01
Cellular Toxicity and Oxidative Stress Concerns
379 papers · 21.5% of this block
▼ -20% share2022→2025 share of research on this subject
Studies caution about in‑vitro and in‑vivo models showing stress responses to nanomaterials and pollutants.
In vivo · Flow cytometry · In vitro · Oxidative stress
“Effects of Microplastics on Cell Viability, Phagocytic Activity and Oxidative Stress in Human Peripheral Blood Mononuclear Cells”
379 of these papers raise it as a problem
Cautions · theme 02
Genomic Selection Limits in Breeding
257 papers · 14.6% of this block
▲ +25% share2022→2025 share of research on this subject
Research warns of practical and theoretical hurdles when applying genomic selection to crops and livestock.
Agriculture · Selection · Production · Trait
“Genomic selection in plant breeding: from theory to practice”
257 of these papers raise it as a problem
Cautions · theme 03
Feed Additive Safety and Efficacy
245 papers · 13.9% of this block
▼ -17% share2022→2025 share of research on this subject
Papers advise careful evaluation of bioactive feed additives for animal health and environmental impact.
Feed additive · Animal feed · Feed conversion ratio · Health benefits
“Natural Bioactive Compounds as Feed Additives: Strategies for Sustainable and Functional Livestock Production”
245 of these papers raise it as a problem
Cautions · theme 04
Food Contaminant Regulatory Uncertainty
240 papers · 13.6% of this block
▲ +14% share2022→2025 share of research on this subject
Works highlight gaps in safety data and regulatory frameworks for emerging food contaminants and additives.
Food safety · Hygiene · Contamination · Food contaminant
“Caffeine (1, 3, 7‐trimethylxanthine) in Foods: A Comprehensive Review on Consumption, Functionality, Safety, and Regulatory Matters”
240 of these papers raise it as a problem
Cautions · theme 05
DNA Damage and Repair Methodology Gaps
239 papers · 13.5% of this block
▼ -32% share2022→2025 share of research on this subject
Studies point to limitations in detecting and interpreting DNA damage and repair mechanisms in health research.
Gene · DNA damage · DNA repair · Gene expression
“Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations”
239 of these papers raise it as a problem
Cautions · theme 06
Co‑Selection of Resistance Factors
206 papers · 11.7% of this block
▲ +10% share2022→2025 share of research on this subject
Research stresses the risk of simultaneous selection for antibiotics, biocides, and heavy‑metal resistance.
Antibiotic resistance · Antibiotics · Antimicrobial · Bacteria
“Antibiotic use in food animals worldwide, with a focus on Africa: Pluses and minuses”
206 of these papers raise it as a problem
Cautions · theme 07
Pesticide Resistance Management Risks
199 papers · 11.3% of this block
▲ +16% share2022→2025 share of research on this subject
Papers caution about dose strategies and ecological impacts that may foster pesticide resistance.
Pesticide · Integrated pest management · PEST analysis · Biological pest control
“The use of fungal entomopathogens as endophytes in biological control: a review”
199 of these papers raise it as a problem
Opportunities22,038 papers · 7 recurring themes
Opportunities · theme 01
Advanced Antibody and Imaging Techniques
1,044 papers · 17.4% of this block
▼ -18% share2022→2025 share of research on this subject
Opportunities arise from novel antibodies, fluorescence methods, and flow cytometry for in‑vivo diagnostics.
Antibody · In vivo · Fluorescence · Flow cytometry
“Figure 4 from Ancestrally Diverse Autologous Patient-Derived Organoid–Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcom”
Opportunities · theme 02
Gene Modulation for Disease Therapy
1,032 papers · 17.2% of this block
▼ -26% share2022→2025 share of research on this subject
Research explores targeted gene knockdown and regulation to control apoptosis and cell growth in disease contexts.
Downregulation and upregulation · Apoptosis · Gene knockdown · Cell growth
“Fat Mass and Obesity‐Associated Protein Contributes to Tumorigenesis and Drug Resistance of Diffuse Large B‐Cell Lymphoma by Suppressing <sc”
Opportunities · theme 03
Functional Plant‑Based Foods
878 papers · 14.6% of this block
▲ +68% share2022→2025 share of research on this subject
Studies promote plant‑derived ingredients with antioxidant properties for health‑focused, sustainable nutrition.
Health benefits · Functional food · Ingredient · Antioxidant
“Plant-based functional foods for healthy aging: current trends, bioactive compounds, and future perspectives”
Opportunities · theme 04
Epigenetic and RNA‑Based Diagnostics
823 papers · 13.7% of this block
▼ -32% share2022→2025 share of research on this subject
Works develop DNA methylation and messenger‑RNA markers for early detection of genetic disorders.
Gene · DNA methylation · Messenger RNA · DNA damage
“Convergent DNA methylation abnormalities at enhancers and bivalent promoters in human growth disorders”
Opportunities · theme 05
Novel Antimicrobials and Biocontrol Agents
809 papers · 13.5% of this block
▲ +25% share2022→2025 share of research on this subject
Research identifies plant‑derived compounds and postbiotic products as new tools against resistant microbes.
Antimicrobial · Antibiotic resistance · Biological pest control · Bacteria
“Plants as sources of new antimicrobials and resistance-modifying agents”
Opportunities · theme 06
Genetic Trait Improvement in Crops
717 papers · 11.9% of this block
▼ -22% share2022→2025 share of research on this subject
Papers highlight quantitative trait locus mapping and selection to boost yield and stress resilience.
Germplasm · Trait · Quantitative trait locus · Selection
“Evaluation of Genetic Variability and Trait Interrelationships Using Advanced Wheat Lines to Increase Yield”
Opportunities · theme 07
Sustainable Biomass Conversion
697 papers · 11.6% of this block
▲ +29% share2022→2025 share of research on this subject
Studies showcase microbial fermentation and by‑product valorisation for renewable biofuels and bioactive compounds.
Biomass · Sustainability · Agriculture · Biofuel
“Microbial Fermentation: A Sustainable Strategy for Producing High-Value Bioactive Compounds for Agriculture, Animal Feed, and Human Health”
Which of these themes are growing fastest
Tracks how the share of research themes changes worldwide between 2022 and 2025.
Problems
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Food Safety and Processing Risks▲+41%
Plant Disease Management Constraints▲+35%
Crop Nutrition and Food‑Security Bottlenecks▲+23%
Sustainable Biofuel and Biorefinery Challenges▲+11%
Antimicrobial Resistance Across Sectors▲+10%
Gene Expression and mRNA Therapeutics Issues▼-31%
Data Quality and Reporting Inconsistencies▼-32%
Cautions
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Genomic Selection Limits in Breeding▲+25%
Pesticide Resistance Management Risks▲+16%
Food Contaminant Regulatory Uncertainty▲+14%
Co‑Selection of Resistance Factors▲+10%
Feed Additive Safety and Efficacy▼-17%
Cellular Toxicity and Oxidative Stress Concerns▼-20%
DNA Damage and Repair Methodology Gaps▼-32%
Opportunities
how much more (or less) of the world’s research on this subject each theme took up, 2022→2025
gaining sharelosing share
Functional Plant‑Based Foods▲+68%
Sustainable Biomass Conversion▲+29%
Novel Antimicrobials and Biocontrol Agents▲+25%
Advanced Antibody and Imaging Techniques▼-18%
Genetic Trait Improvement in Crops▼-22%
Gene Modulation for Disease Therapy▼-26%
Epigenetic and RNA‑Based Diagnostics▼-32%
Prism
Go deeper on Life Sciences research and innovation
Research themes, patent activity and the companies commercialising them, in one place.
Keep going
Track Life Sciences in China beyond this page
Radar finds and filters the companies. Prism watches what is being said about them.
About this data: built from Fliar's company, founder, funding, hiring, jobs, news and research trackers, covering China. Counts are of companies we track, not of every company that exists. Updated August 2026.
Contact details
Reach this founder through Fliar Radar
Direct contact details for the people on this page are held in Fliar Radar, behind its own access controls.